Team

We have fully integrated a critical mass of expertise in structural biology methods with medicinal chemistry and the experience to develop the full range of assays critical in discovery of drug candidates. That’s what makes our research team unique.

We have a strong, interdisciplinary team with expertise in:

  • Medicinal and Computational chemistry
  • Structural & Biophysical sciences
  • Cellular and Biochemical sciences
  • DMPK studies

This team has produced six development candidates in the past seven years, across a range of biological disciplines such as CNS, Pain and Oncology. These strengths have been endorsed through a continuing series of research collaborations with major pharmaceutical companies.

Our scientists are recognised as influential world leaders in fragment-based discovery, invited to speak at major conferences and with highly cited publications.

Latest News

Vernalis plc receives a $2 million milestone payment from one of its drug discovery collaborations

Vernalis plc announced today that it has received a $2m milestone under one of its existing research collaborations to discover novel small molecules against an undisclosed target utilising Vernalis' fragment and structure-based drug discovery platform.

Read more ...

Product Pipeline

For more information on our pipeline, click below to visit Vernalis plc

Commercial Pipeline

Comm-thumbnailExplore the pipeline ...

 

NCE Pipeline

NCE-thumbnailExplore the pipeline ...

 

Contact Vernalis Research

T: (0)1223 895555
F: (0)1223 895556

Contact information
Maps and directions
Contact form

Fact Sheet

For more information on Vernalis, click on the below image to download a copy of our fact sheet

Vernalis Factsheet May 2015 Page 1